Novartis Menveo vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial (07 May 2008) First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra coverage and that can be used in all at-risk agegroups," said Keith S. Reisinger, MD... these four vaccine-preventable serogroups in people across agegroups from infancy... in adolescents 11-18 years of age compared to MenactraŽ. Infection with any...
New data show Menveo to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants (11 Jan 2008) Data in JAMA show Menveo may provide infants protection against four of the most common meningococcal serogroups - A, C, W-135 and Y response across all agegroups. Novartis plans regulatory submissions for Menveo... infants using a schedule beginning at two months of age against four of the most... immune response for this age group. These new results build on numerous other...
Top